Trait: female reproductive organ cancer

Trait Information
Identifier MONDO_0001416
Description A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma. [NCIT: C4913]
Trait category
Cancer
Synonyms 15 synonyms
  • cancer of female reproductive organ
  • female reproductive cancer
  • female reproductive organ cancer
  • gynecologic cancer
  • malignant female reproductive organ neoplasm
  • malignant female reproductive system neoplasm
  • malignant female reproductive system tumor
  • malignant gynecologic neoplasm
  • malignant gynecologic tumor
  • malignant neoplasm of female genital organ
  • malignant neoplasm of female reproductive organ
  • malignant neoplasm of female reproductive system
  • malignant neoplasm of the female reproductive system
  • malignant tumor of female reproductive system
  • malignant tumor of the female reproductive system
Mapped term(s) 6 mapped terms
  • DOID:120
  • ICD10:C51.C58
  • ICD10:C57
  • ICD9:184
  • NCIT:C4913
  • SCTID:126907002
Child trait(s) 6 child traits

Associated Polygenic Score(s)

Note: This table shows all PGS for "female reproductive organ cancer" and any child terms of this trait in the EFO hierarchy by default.
Polygenic Score (PGS) ID PGS Name PGS Publication (PGP) ID Reported Trait Mapped Trait(s) (Ontology) Number of Variants PGS Scoring File (FTP Link)
PGS000048 OCPRS_Overall PGP000033 Kuchenbaecker KB et al. J Natl Cancer Inst (2017) Ovarian cancer ovarian carcinoma 17 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000048/ScoringFiles/PGS000048.txt.gz
PGS000068 PRS_EOC PGP000048 Yang X et al. J Med Genet (2018) Epithelial ovarian cancer ovarian carcinoma 15 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000068/ScoringFiles/PGS000068.txt.gz
PGS000069 PRS_sEOC PGP000048 Yang X et al. J Med Genet (2018) Serous epithelial ovarian cancer ovarian serous carcinoma 15 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000069/ScoringFiles/PGS000069.txt.gz
PGS000073 CC_Cervix PGP000050 Graff RE et al. bioRxiv (2020) Pre Cervical cancer cervical carcinoma 10 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000073/ScoringFiles/PGS000073.txt.gz
PGS000075 CC_Endo PGP000050 Graff RE et al. bioRxiv (2020) Pre Endometrial cancer endometrial carcinoma 9 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000075/ScoringFiles/PGS000075.txt.gz
PGS000082 CC_Ovary PGP000050 Graff RE et al. bioRxiv (2020) Pre Ovarian cancer ovarian carcinoma 36 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000082/ScoringFiles/PGS000082.txt.gz
PGS000158 cGRS_Ovarian PGP000075 Shi Z et al. Cancer Med (2019) Ovarian cancer ovarian carcinoma 11 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000158/ScoringFiles/PGS000158.txt.gz
PGS000351 PRS_EOC PGP000117 Barnes DR et al. Genet Med (2020) Invasive epithelial ovarian cancer ovarian carcinoma 30 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000351/ScoringFiles/PGS000351.txt.gz
PGS000352 PRS_HGS PGP000117 Barnes DR et al. Genet Med (2020) High grade serous ovarian cancer high grade ovarian serous adenocarcinoma 22 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000352/ScoringFiles/PGS000352.txt.gz
PGS000541 PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of uterus uterine cancer 18 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000541/ScoringFiles/PGS000541.txt.gz
PGS000542 PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of uterus uterine cancer 20 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000542/ScoringFiles/PGS000542.txt.gz
PGS000543 PRSWEB_PHECODE184_C3-FEMALE-GENITAL_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of other female genital organs female reproductive organ cancer 8 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000543/ScoringFiles/PGS000543.txt.gz

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID) 		Evaluated Score PGS Sample Set ID
(PSS ID) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM000193 PGS000073 (CC_Cervix) PSS000112 PGP000050
Graff RE et al. (2020) Pre		 Reported Trait: Cervical cancer OR: 1.22 [1.19, 1.25] — — Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM000195 PGS000075 (CC_Endo) PSS000114 PGP000050
Graff RE et al. (2020) Pre		 Reported Trait: Endometrial cancer OR: 1.19 [1.14, 1.24] — — Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM000202 PGS000082 (CC_Ovary) PSS000121 PGP000050
Graff RE et al. (2020) Pre		 Reported Trait: Ovarian cancer OR: 1.14 [1.08, 1.2] — — Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM000112 PGS000048 (OCPRS_Overall) PSS000072 PGP000033
Kuchenbaecker KB et al. (2017) 		Reported Trait: Ovarian cancer in BRCA1 mutation carriers HR: 1.28 [1.22, 1.34] C-index: 0.579 [0.559, 0.6] — Country, birth year —
PPM000113 PGS000048 (OCPRS_Overall) PSS000073 PGP000033
Kuchenbaecker KB et al. (2017) 		Reported Trait: Ovarian cancer in BRCA2 mutation carriers HR: 1.49 [1.34, 1.65] C-index: 0.628 [0.592, 0.665] — Country, birth year —
PPM000188 PGS000068 (PRS_EOC) PSS000108 PGP000048
Yang X et al. (2018) 		Reported Trait: all invasive epithelial ovarian cancer OR: 1.32 [1.21, 1.45] C-index: 0.58 [0.55, 0.6] — — —
PPM000189 PGS000069 (PRS_sEOC) PSS000108 PGP000048
Yang X et al. (2018) 		Reported Trait: serous epithelial ovarian cancer OR: 1.43 [1.29, 1.58] C-index: 0.6 [0.57, 0.63] — — —
PPM000489 PGS000158 (cGRS_Ovarian) PSS000278 PGP000075
Shi Z et al. (2019) 		Reported Trait: Ovarian cancer — — Odds Ratio (OR; high vs. average risk groups): 1.63 [1.3, 2.06] — —
PPM000478 PGS000158 (cGRS_Ovarian) PSS000278 PGP000075
Shi Z et al. (2019) 		Reported Trait: Ovarian cancer — — Mean realative risk: 1.12 [1.08, 1.16]
Wilcoxon test (case vs. control) p-value: 0.00015		 — —
PPM001030 PGS000351 (PRS_EOC) PSS000524 PGP000117
Barnes DR et al. (2020) 		Reported Trait: Ovarian cancer in BRCA1 carriers HR: 1.31 [1.24, 1.39] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001031 PGS000351 (PRS_EOC) PSS000528 PGP000117
Barnes DR et al. (2020) 		Reported Trait: Ovarian cancer in BRCA2 carriers HR: 1.42 [1.28, 1.58] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001032 PGS000352 (PRS_HGS) PSS000524 PGP000117
Barnes DR et al. (2020) 		Reported Trait: Ovarian cancer in BRCA1 carriers HR: 1.32 [1.25, 1.4] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001033 PGS000352 (PRS_HGS) PSS000528 PGP000117
Barnes DR et al. (2020) 		Reported Trait: Ovarian cancer in BRCA2 carriers HR: 1.43 [1.29, 1.59] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001036 PGS000352 (PRS_HGS) PSS000530 PGP000117
Barnes DR et al. (2020) 		Reported Trait: Incident ovarian cancer in BRCA1 carriers HR: 1.28 [1.06, 1.55] — — family history of the appropriate cancer in first- and second-degree relatives —
PPM001037 PGS000352 (PRS_HGS) PSS000532 PGP000117
Barnes DR et al. (2020) 		Reported Trait: Incident ovarian cancer in BRCA2 carriers HR: 1.45 [1.13, 1.86] — — family history of the appropriate cancer in first- and second-degree relatives —
PPM001228 PGS000543 (PRSWEB_PHECODE184_C3-FEMALE-GENITAL_PT_MGI_20200608) PSS000551 PGP000118
Fritsche LG et al. (2020) 		Reported Trait: Cancer of other female genital organs OR: 1.144 [1.043, 1.255]
β: 0.135 (0.0472)		 AUROC: 0.51 [0.483, 0.537] Nagelkerke's Pseudo-R²: 0.00332
Brier score: 0.0836
Odds Ratio (OR, top 1% vs. Rest): 1.63 [0.743, 3.57]		 age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE184_C3-FEMALE-GENITAL_PT_MGI_20200608
PPM001226 PGS000541 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608) PSS000571 PGP000118
Fritsche LG et al. (2020) 		Reported Trait: Malignant neoplasm of uterus OR: 1.311 [1.209, 1.422]
β: 0.271 (0.0415)		 AUROC: 0.576 [0.553, 0.6] Nagelkerke's Pseudo-R²: 0.0133
Brier score: 0.082
Odds Ratio (OR, top 1% vs. Rest): 2.12 [1.17, 3.84]		 age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608
PPM001227 PGS000542 (PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608) PSS000571 PGP000118
Fritsche LG et al. (2020) 		Reported Trait: Malignant neoplasm of uterus OR: 1.302 [1.2, 1.413]
β: 0.264 (0.0416)		 AUROC: 0.572 [0.549, 0.596] Nagelkerke's Pseudo-R²: 0.0126
Brier score: 0.082
Odds Ratio (OR, top 1% vs. Rest): 2.6 [1.5, 4.51]		 age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608

Evaluated Samples

PGS Sample Set ID
(PSS ID) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000072 BRCA1 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis —
[
  • 2,462 cases
  • , 12,790 controls
]
,
0.0 % Male samples
 — European Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry CIMBA Median censoring age (cases) = 50
PSS000121 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27040 —
[
  • 1,261 cases
  • , 219,648 controls
]
,
0.0 % Male samples
 — European — GERA, UKB —
PSS000530 To assess associationss between the PRS and ovarian cancer risk, eligibility was restricted to women who had not been diagnosed with ovarian cancer and had not had RRSO at the time of baselinne questionnaire completion. Carriers diagnosed with invasive ovarian, fallopian tube, or peritoneal cancer during the follow-up were considered affected. —
[
  • 108 cases
  • , 3,044 controls
]
,
0.0 % Male samples
 — European — 61 cohorts
  • BCFR
  • ,BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT TEAM
  • ,CopBCS
  • ,DFCI
  • ,DKFZ
  • ,Demokritos
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,IBCCS
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWEBCS
  • ,UC
  • ,UCLA
  • ,UCSANFRAN
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS000528 — —
[
  • 718 cases
  • , 11,621 controls
]
,
0.0 % Male samples
 — European — 59 cohorts
  • BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT TEAM
  • ,CopBCS
  • ,DFCI
  • ,DKFZ
  • ,Demokritos
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWEBCS
  • ,UC
  • ,UCLA
  • ,UCSANFRAN
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS000108 Adjudicated endpoint determined from medical notes by an outcome review committee Mean = 11.1 years
Iqr = [10.0, 12.0] years
[
  • 750 cases
  • , 1,428 controls
]
,
0.0 % Male samples
 Mean = 63.0 years
Range = [50.0, 74.0] years		 European — UKCTOCS —
PSS000108 Adjudicated endpoint determined from medical notes by an outcome review committee Mean = 11.1 years
Iqr = [10.0, 12.0] years
[
  • 489 cases
  • , 1,428 controls
]
,
0.0 % Male samples
 Mean = 63.0 years
Range = [50.0, 74.0] years		 European — UKCTOCS —
PSS000571 PheCode:182; ICD9:179, 182, 182.0, 182.1, 182.8, 233.2; ICD10:C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55, D07.0 —
[
  • 634 cases
  • , 6,353 controls
]
 — European — UKB —
PSS000524 — —
[
  • 2,068 cases
  • , 16,867 controls
]
,
0.0 % Male samples
 — European — 59 cohorts
  • BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT TEAM
  • ,CopBCS
  • ,DFCI
  • ,DKFZ
  • ,Demokritos
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWEBCS
  • ,UC
  • ,UCLA
  • ,UCSANFRAN
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS000112 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27010 —
[
  • 6,568 cases
  • , 219,648 controls
]
,
0.0 % Male samples
 — European — GERA, UKB —
PSS000073 BRCA2 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis —
[
  • 631 cases
  • , 7,580 controls
]
,
0.0 % Male samples
 — European Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry CIMBA Median censoring age (cases) = 57
PSS000114 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27020 —
[
  • 2,051 cases
  • , 219,648 controls
]
,
0.0 % Male samples
 — European — GERA, UKB —
PSS000278 Primary tumor samples from TCGA —
[
  • 531 cases
  • , 0 controls
]
,
0.0 % Male samples
 Mean = 60.0 years
Sd = 12.0 years		 European — TCGA —
PSS000278 — —
[
  • 0 cases
  • , 7,020 controls
]
,
0.0 % Male samples
 — European — eMERGE —
PSS000551 PheCode:184; ICD9CM:181, 183.0, 183.2, 183.3, 183.4, 183.5, 183.8, 183.9, 184.0, 184.1, 184.2, 184.3, 184.4, 184.8, 184.9, 233.30, 233.31, 233.32, 233.39, 236.0, 236.1, 236.2, 236.3, V10.40, V10.43, V10.44; ICD10CM:C51, C51.0, C51.1, C51.2, C51.8, C51.9, C52, C56, C56.1, C56.2, C56.9, C57, C57.0, C57.00, C57.01, C57.02, C57.1, C57.10, C57.11, C57.12, C57.2, C57.20, C57.21, C57.22, C57.3, C57.4, C57.7, C57.8, C57.9, C58, D07.1, D07.2, D07.3, D07.30, D07.39, D39, D39.0, D39.1, D39.10, D39.11, D39.12, D39.2, D39.8, D39.9, N90.3 —
[
  • 453 cases
  • , 4,452 controls
]
 — European — MGI —
PSS000532 To assess associationss between the PRS and ovarian cancer risk, eligibility was restricted to women who had not been diagnosed with ovarian cancer and had not had RRSO at the time of baseline questionnaire completion. Carriers diagnosed with invasive ovarian, fallopian tbe, or peritoneal cancer during the follow-up were considered affected. —
[
  • 56 cases
  • , 2,439 controls
]
,
0.0 % Male samples
 — European — 61 cohorts
  • BCFR
  • ,BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT TEAM
  • ,CopBCS
  • ,DFCI
  • ,DKFZ
  • ,Demokritos
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,IBCCS
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWEBCS
  • ,UC
  • ,UCLA
  • ,UCSANFRAN
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —